Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-D: Vitamin D in Metastatic Breast Cancer
NCT02186015Phase 2Completed
- Sponsor
- Loyola University Chicago
- Start
- Feb 2015
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
Phase 2, open-label trial in Vitamin D deficiency (VDD) and breast cancer (2 arms), sponsored by Loyola University Chicago. Primary endpoint: Serum 25-hydroxyvitamin D at 8 weeks. Started Feb 2015; status: completed.
02
Conditions
Vitamin D deficiency (VDD)breast cancer
Beyond the preview
Go deeper on NCT02186015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186015.